NEW YORK, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Brooklyn Minds, a concierge mental health facility providing comprehensive and highly collaborative child, adolescent and adult mental health services, announced today that patients can now receive BrainsWay’s Deep Transcranial Magnetic Stimulation therapy for Obsessive-Compulsive Disorder (OCD). The facility has been using Deep TMS for patients suffering from depression in its Manhattan and Williamsburg locations since 2016.

“In New York State, the prevalence of adults coping with a severe mental illness during 2014 was 598,000 adults, or about 3.9 percent of the population,” said Owen Muir, M.D., Medical Director at Brooklyn Minds. “Our facility has been using Deep TMS to treat patients suffering from depression with exceptionally high response and remission rates. Upon completion of therapy, 89 percent of our patients reported having greater than a 50 percent decrease in depressive symptoms, and 58 percent reported full remission. Impressed by the positive treatment responses of Deep TMS for depression, we are thrilled to offer hope for our patients suffering from OCD as well.”

Deep TMS is a non-invasive technology that sends magnetic pulses into the deep structures of the region of the brain involved with OCD, the anterior cingulate cortex. Prior to administering Deep TMS therapy, practitioners prompt OCD behavior for optimal effectiveness. Brooklyn Minds monitors response rates for Deep TMS with weekly standardized assessments developed at Yale and Brown Universities.

Brooklyn Minds has offered over 4,000 customized treatments to date, administering over 120 treatment sessions per week across facilities. In addition to offering Deep TMS therapy for OCD and depression, patients can receive outpatient psychiatric care and therapy in one-on-one, family or group settings. Additional services include psycho-educational testing, case management, clinical supervision, post-doctoral training and a new mental health companion service. Using one of the only on-model, outpatient, mentalization-based treatment (MBT) programs in the United States, Brooklyn Minds cares for individuals with personality disorders and other complex problems. 

About BrainsWay
BrainsWay Ltd./ BrainsWay USA (TASE: BRIN), is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders. The medical system developed and manufactured by the company is based on a unique breakthrough technology called Deep TMS, which can reach significant depth and breadth of the brain and produce broad stimulation and functional modulation of targeted brain areas. In the U.S., the Company’s device has been FDA cleared for the treatment of major depressive disorder (MDD) since 2013 and is now FDA cleared (De-Novo) for the treatment of Obsessive Compulsive Disorder (OCD). The Company's systems have also received CE clearance and are sold worldwide for the treatment of various brain disorders.

About Brooklyn Minds:
Brooklyn Minds provides customized and comprehensive mental health care to individuals and families across the lifespan. We take pride in our collaborative philosophy. Our concierge approach means greater clinician access and dedicated administrative support to make the process of getting help go smoothly, rather than add additional stress. The practice offers specialized therapies for a wide range of psychological concerns from tensions that come with typical child development to the complexities associated with chronic suicidal ideation that lead to intensive placements such as residentials or inpatient hospitals.

BrainsWay Media Contact:
Nechama Feuerstein

Brooklyn Minds contact:
Owen Muir, M.D.
Medical Director